^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Ovarian Serous Adenocarcinoma

    Related cancers:
    1d
    Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models. (PubMed, Int J Gynecol Cancer)
    FOLR1 is overexpressed in a large percentage of low-grade serous ovarian cancers. Mirvetuximab soravtansine may represent a novel treatment option for low-grade serous ovarian cancer patients progressing after standard treatment modalities. Clinical trials with mirvetuximab soravtansine in FOLR1-positive low-grade serous ovarian cancers are warranted.
    Preclinical • Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression • FOLR1 overexpression • FOLR1 positive
    |
    Elahere (mirvetuximab soravtansine-gynx)
    2d
    RAMP201J: A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients (clinicaltrials.gov)
    P2, N=16, Active, not recruiting, Verastem, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Avmapki (avutometinib) • Fakzynja (defactinib)
    3d
    Therapeutic advances and molecular insights in low-grade serous ovarian carcinoma. (PubMed, Bull Cancer)
    MEK inhibitors, especially trametinib and avutometinib in combination with defactinib, have recently demonstrated improved outcomes in recurrent disease, while new combination strategies are under active evaluation to overcome resistance mechanisms. Immunotherapy remains of limited efficacy, though biomarker-driven combinations are explored. Ongoing biomarker-guided trials are expected to refine treatment paradigms.
    Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    Mekinist (trametinib) • Avmapki (avutometinib) • Fakzynja (defactinib)
    5d
    Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial. (PubMed, Tumori)
    Early findings suggest letrozole is well tolerated and may represent a viable therapeutic option for hormone receptor-positive LGSCO. Ongoing molecular and clinical analyses will clarify its role in this rare subtype.
    P3 data • Journal • BRCA Biomarker
    |
    PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • MUC16 (Mucin 16, Cell Surface Associated) • RAD51 (RAD51 Homolog A)
    |
    HR positive • PGR positive
    |
    carboplatin • paclitaxel • letrozole
    5d
    Divergent oncogenic signaling and immune microenvironment changes in low-grade serous ovarian cancer patients undergoing intraperitoneal chemotherapy. (PubMed, NPJ Precis Oncol)
    Archetype analysis revealed dynamic shifts in metabolic and immune-related subpopulations in the responder tumors, while immunoprofiling showed greater immunosuppression in non-responder tumors. Despite the small cohort, these exploratory observations highlight tumor adaptation and underscore the need for multi-targeted therapies addressing proliferation, stress, survival, and immune evasion.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    7d
    Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026). (PubMed, J Clin Oncol)
    Ribociclib plus letrozole met the primary end point, achieving meaningful response rates and durable disease control in recurrent LGSOC. The safety profile was consistent with prior CDK4/6 inhibitor studies. This combination represents a therapeutic option in this rare and genomically distinct subtype.
    P2 data • Journal
    |
    ER (Estrogen receptor)
    |
    HR positive
    |
    Kisqali (ribociclib) • letrozole
    8d
    Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancer. (PubMed, Clin Cancer Res)
    This exploratory analysis suggests pERK expression and mutation of KRAS/BRAF/NRAS are candidate biomarkers of improved PFS and response to trametinib, respectively.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF mutation • NRAS mutation • RAS mutation • KRAS amplification
    |
    Mekinist (trametinib)
    9d
    Genomic Analysis of Low-Grade Serous Ovarian Cancer: Clinical and Biological Insights. (PubMed, Cureus)
    The cooperative GOG 281/LOGS trial showed that trametinib, an MEK inhibitor (MEKi), was significantly more effective than standard-of-care options (including chemotherapy or hormonal therapy) in increasing progression-free survival (median PFS 13.0 months vs. 7.2 months; hazard ratio 0.48, p < 0.001)...Genomic and multi-omic profiling have revealed actionable vulnerabilities and precision oncology approaches. The advent of biomarker-directed trials, molecular subtyping incorporation, and innovative computational strategies is likely to gradually ameliorate therapy selection and, thereby, finally improve long-term outcomes for patients with this complex disease.
    Review • Journal • Tumor mutational burden • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • NF1 (Neurofibromin 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CDH1 (Cadherin 1) • MIR7 (MicroRNA 7) • RASSF1 (Ras Association Domain Family Member 1)
    |
    TP53 mutation • KRAS mutation • BRAF mutation • NRAS mutation • HER-2 mutation • CDKN2A deletion
    |
    Mekinist (trametinib)
    10d
    Genomics of ovarian cancers and the potential of precision medicine. (PubMed, Ther Adv Med Oncol)
    We focus on PARPi combinations for HGSOC, MAPK pathway inhibitors for LGSOC, cell cycle checkpoint inhibitors for OC with CCNE1 amplification, the potential of immune checkpoint inhibitors in OCCC and encouraging, as yet preliminary, responses for antibody-drug conjugate-based therapy. Thus, OC type-specific genomic susceptibilities provide direction for personalised therapy in OC.
    Review • Journal • BRCA Biomarker • PARP Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • CCNE1 (Cyclin E1)
    18d
    NIRADO: Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (clinicaltrials.gov)
    P2, N=51, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Dec 2027 --> Feb 2025 | Suspended --> Terminated; Abandon of the partner, GSK
    Trial completion date • Trial termination • Pan tumor • Platinum sensitive
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • ARID2 (AT-Rich Interaction Domain 2) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)
    |
    HER-2 positive • HER-2 amplification • DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    23d
    MicroRNA Signatures in Serous Ovarian Cancer: A Comparison of Prognostic Marker Targets in African Americans and Caucasians. (PubMed, Diseases)
    Pathway enrichment and gene ontology analyses (miRTargetLink2.0, Enrichr) revealed interconnected regulatory networks linking miR-192, miR-16-5p, miR-143-3p, and miR-20a-5p to ITGB1; miR-143-3p/miR-145-5p to BRAF; and miR-16-5p and miR-30c/d to TIMP3. Collectively, these findings identify distinct miRNA-mRNA regulatory signatures-particularly the miR-192-5p-ITGB1/TIMP3 axis-as potential clinically relevant biomarkers that may contribute to racial disparities and disease progression in ovarian cancer.
    Journal
    |
    BRAF (B-raf proto-oncogene) • MIR192 (MicroRNA 192) • MIR143 (MicroRNA 143) • MIR16 (MicroRNA 16) • MIR30D (MicroRNA 30d) • ITGB1 (Integrin Subunit Beta 1) • MIR145 (MicroRNA 145) • MIR20A (MicroRNA 20a) • MIR30C • TIMP3 (TIMP Metallopeptidase Inhibitor 3)
    25d
    Mechanistic insights into c-Met rs368750834 mutation and a bifunctional CAR-T strategy for serous ovarian carcinoma. (PubMed, J Ovarian Res)
    These cells exhibited markedly enhanced cytotoxicity against tumour cells overexpressing c-Met, accompanied by increased release of key effector cytokines such as interferon-γ. This research framework offers a precise, synergistic therapeutic strategy to overcome limitations in CAR-T therapy response within serous ovarian carcinoma.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • IFNG (Interferon, gamma)
    |
    MET overexpression • MET mutation